Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Pfizer with MYLAN INC. - US - Equitymaster
  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

PFIZER vs MYLAN (US) - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More


Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More



5-Yr Chart
Click to enlarge
High Rs2,7243,830-   
Low Rs1,6112,699-   
Sales per share (Unadj.) Rs440.91,311.3-  
Earnings per share (Unadj.) Rs48.7158.0-  
Cash flow per share (Unadj.) Rs75.8254.3-  
Dividends per share (Unadj.) Rs15.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs462.9651.9-  
Shares outstanding (eoy) m45.75378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x4.92.5 197.5%   
Avg P/E ratio x44.520.7 215.4%  
P/CF ratio (eoy) x28.612.8 222.8%  
Price / Book Value ratio x4.75.0 93.5%  
Dividend payout %30.80-   
Avg Mkt Cap Rs m99,1631,235,346 8.0%   
No. of employees `0002.925.0 11.6%   
Total wages/salary Rs m2,7580-   
Avg. sales/employee Rs Th6,981.719,846.6 35.2%   
Avg. wages/employee Rs Th954.50-   
Avg. net profit/employee Rs Th771.12,390.8 32.3%   
Net Sales Rs m20,170496,164 4.1%  
Other income Rs m857-2,892 -29.6%   
Total revenues Rs m21,028493,272 4.3%   
Gross profit Rs m4,310123,398 3.5%  
Depreciation Rs m1,23936,441 3.4%   
Interest Rs m521,402 0.0%   
Profit before tax Rs m3,92362,663 6.3%   
Minority Interest Rs m0-257 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m990-   
Tax Rs m1,7942,635 68.1%   
Profit after tax Rs m2,22859,771 3.7%  
Gross profit margin %21.424.9 85.9%  
Effective tax rate %45.74.2 1,087.6%   
Net profit margin %11.012.0 91.7%  
Current assets Rs m16,299436,194 3.7%   
Current liabilities Rs m7,594341,017 2.2%   
Net working cap to sales %43.219.2 225.0%  
Current ratio x2.11.3 167.8%  
Inventory Days Days6578 83.6%  
Debtors Days Days26107 24.0%  
Net fixed assets Rs m8,622114,786 7.5%   
Share capital Rs m45817,546 2.6%   
"Free" reserves Rs m20,7220-   
Net worth Rs m21,180246,643 8.6%   
Long term debt Rs m25368,460 0.0%   
Total assets Rs m29,137993,454 2.9%  
Interest coverage x755.53.9 19,233.6%   
Debt to equity ratio x01.5 0.1%  
Sales to assets ratio x0.70.5 138.6%   
Return on assets %7.78.2 93.8%  
Return on equity %10.524.2 43.4%  
Return on capital %19.013.6 139.4%  
Exports to sales %0.10-   
Imports to sales %17.50-   
Net fx Rs m-880-   
From Operations Rs m3,43665,221 5.3%  
From Investments Rs m-6,991-51,435 13.6%  
From Financial Activity Rs m-619-17,186 3.6%  
Net Cashflow Rs m-4,174-3,400 122.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.27 Rs / USD

Compare PFIZER With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  


Today's Market

Sensex Opens Flat; PSU & Healthcare Stocks Top Losers(09:30 am)

Asian equities are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1.20% while the Hang Seng is up 0.61%. The Shanghai Composite is trading up by 0.45%.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Feb 20, 2018 09:45 AM